journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Musculoskeletal Disease

journal
https://www.readbyqxmd.com/read/27721905/combination-therapy-with-biologic-agents-in-rheumatic-diseases-current-and-future-prospects
#1
Kentaro Inui, Tatsuya Koike
Strategies in rheumatoid arthritis (RA) based on 'treat to target' aim to control disease activity, minimize structural damage, and promote longer life. Several disease-modifying antirheumatic drugs (DMARDs) have been shown to be effective including biological DMARDs (bDMARDs). Treatment guidelines and recommendations for RA have also been published. According to those guidelines, conventional synthetic DMARDs (csDMARDs), as monotherapy or combination therapy, should be used in DMARD-naïve patients, irrespective of the addition of glucocorticoids (GCs)...
October 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/27721904/managing-cardiovascular-risk-in-patients-with-inflammatory-arthritis-practical-considerations
#2
Anne Tournadre, Sylvain Mathieu, Martin Soubrier
Patients with inflammatory arthritis, such as rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis, have higher rates of cardiovascular mortality. While the increased cardiovascular risk is only explained to some extent, a lot of research is currently conducted to improve our understanding of its pathogenesis, risk stratification, and optimal cardiovascular risk management. This review sought to report epidemiological data pertaining to the cardiovascular disease burden in patients with inflammatory arthritis, underlying mechanisms accounting for excessive cardiovascular risk, along with recommendations regarding risk assessment and management in this patient population...
October 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/27721903/combination-leflunomide-and-methotrexate-in-refractory-rheumatoid-arthritis-a-biologic-sparing-approach
#3
Bridget Hodkinson, Kingsley Ross Magomero, Mohammed Tikly
BACKGROUND: In resource-constrained settings where biologic agents are not widely available, there are limited therapeutic options for patients with rheumatoid arthritis (RA) refractory to other synthetic disease modifying antirheumatic (DMARD) therapies. The aim of this study is to evaluate the effectiveness and safety of leflunomide (LEF) with methotrexate (MTX) in refractory RA. METHODS: A retrospective record review of adult RA patients treated with LEF/MTX...
October 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/27721902/best-performing-definition-of-accelerated-knee-osteoarthritis-data-from-the-osteoarthritis-initiative
#4
Jeffrey B Driban, Alina C Stout, Grace H Lo, Charles B Eaton, Lori Lyn Price, Bing Lu, Mary F Barbe, Timothy E McAlindon
BACKGROUND: We evaluated agreement among several definitions of accelerated knee osteoarthritis (AKOA) and construct validity by comparing their individual associations with injury, age, obesity, and knee pain. METHODS: We selected knees from the Osteoarthritis Initiative that had no radiographic knee osteoarthritis [Kellgren-Lawrence (KL) 0 or 1] at baseline and had high-quality quantitative medial joint space width (JSW) measures on two or more consecutive visits (n = 1655 knees, 1143 participants)...
October 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/27493693/treatment-of-hyperuricemia-in-gout-current-therapeutic-options-latest-developments-and-clinical-implications
#5
REVIEW
Sebastian E Sattui, Angelo L Gaffo
Despite being the most common type of inflammatory arthritis, gout is often poorly managed. Except for febuxostat and pegloticase, research in new therapeutic agents for the management of hyperuricemia in gout remained insufficient for several decades. With emerging evidence of possible roles of hyperuricemia in cardiometabolic comorbidities, as well as more convincing evidence regarding poor outcomes (e.g. disability, recurrent hospital admissions) in patients with uncontrolled gout, several agents are current under development...
August 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/27493692/selected-aspects-of-the-current-management-of-myositis
#6
REVIEW
James Lilleker, Sean Murphy, Robert Cooper
The idiopathic inflammatory myopathies (IIM) are a rare and heterogeneous group of acquired autoimmune muscle disorders, often referred to as 'myositis'. Clinical assessment, together with muscle biopsy findings and autoantibody status are key factors to consider when making a diagnosis of IIM, and in stratification of the 'IIM spectrum' into disease subgroups. Treatment stratified according to serotype (and in the future, likely also genotype) is increasingly being used to take account of the heterogeneity within the IIM spectrum...
August 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/27493691/maternal-vitamin-d-levels-during-pregnancy-and-neonatal-health-evidence-to-date-and-clinical-implications
#7
REVIEW
Spyridon N Karras, Hana Fakhoury, Giovanna Muscogiuri, William B Grant, Johannes M van den Ouweland, Anna Maria Colao, Kalliopi Kotsa
Low maternal vitamin D levels during pregnancy have been associated with a plethora of adverse neonatal outcomes, including small for gestational age and preterm births, detrimental effect on offspring bone and teeth development, and risk of infectious diseases. Although most observational studies indicate a significant linear relationship between maternal 25-hydroxyvitamin D and the above outcomes, some randomized controlled trials to date are inconclusive, mostly due to differences in study design and supplementation regimen...
August 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/27493690/intravenous-zoledronate-for-osteoporosis-less-might-be-more
#8
REVIEW
Andrew Grey
Annual administration of 5 mg intravenous zoledronate is moderately effective in reducing fracture risk in older adults, decreasing the relative risk of clinical fracture by 33%. However, almost 10 years after its approval for use in clinical practice there remain very substantial uncertainties about the optimal treatment regimen, that is, the lowest dose and/or longest dosing interval that is efficacious. Several pieces of clinical research suggest that the current recommendation for annual administration of 5 mg zoledronate might represent overtreatment...
August 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/27493689/remission-induction-therapies-for-early-rheumatoid-arthritis-evidence-to-date-and-clinical-implications
#9
REVIEW
Francisco Espinoza, Sylvie Fabre, Yves-Marie Pers
Recent guidelines on rheumatoid arthritis (RA) point to the importance of achieving remission as soon as possible during the course of the disease. The appropriate use of antirheumatic drugs is critical, particularly in early RA patients, before 24 weeks, since this is a 'window of opportunity' for treatment to modify disease progression. A treat-to-target strategy added to an aggressive therapeutic approach increases the chance of early remission, particularly in early RA patients. We conducted an overview of current therapeutic strategies leading to remission in early RA patients...
August 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/27247635/cardiovascular-risk-in-rheumatoid-arthritis-assessment-management-and-next-steps
#10
REVIEW
Thomas Zegkos, George Kitas, Theodoros Dimitroulas
Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) morbidity and mortality which cannot be fully explained by traditional CV risk factors; cumulative inflammatory burden and antirheumatic medication-related cardiotoxicity seem to be important contributors. Despite the acknowledgment and appreciation of CV disease burden in RA, optimal management of individuals with RA represents a challenging task which remains suboptimal. To address this need, the European League Against Rheumatism (EULAR) published recommendations suggesting the adaptation of traditional risk scores by using a multiplication factor of 1...
June 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/27247634/how-does-surgery-compare-with-advanced-intra-articular-therapies-in-knee-osteoarthritis-current-thoughts
#11
REVIEW
Peter Wehling, Carsten Moser, William Maixner
The objectives of osteoarthritis (OA) management are to reduce pain and inflammation, slow cartilage degradation, improve function and reduce disability. Current strategies for managing knee OA include nonpharmacological interventions, oral pharmacological treatments, localized intra-articular injections, and surgery. It has become evident that the inflammatory response is a key contributor to the development and progression of knee OA. Signaling pathways involving growth factors and cytokines are being investigated for the development of new therapies that target the underlying biological processes causing the disease...
June 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/27247633/bone-repair-with-skeletal-stem-cells-rationale-progress-to-date-and-clinical-application
#12
REVIEW
Elena A Jones, Peter V Giannoudis, Dimitrios Kouroupis
Bone marrow (BM) contains stem cells for both hematopoietic and nonhematopoietic lineages. Hematopoietic stem cells enable hematopoiesis to occur in a controlled manner in order to accurately compensate for the loss of short- as well as long-lived mature blood cells. The physiological role of nonhematopoietic BM stem cells, often referred to as multipotential stromal cells or skeletal stem cells (SSCs), is less understood. According to an authoritative current opinion, the main function of SSCs is to give rise to cartilage, bone, marrow fat and hematopoiesis-supportive stroma, in a specific sequence during embryonic and postnatal development...
June 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/27047574/trigger-finger-ultrasound-guided-injection-with-an-in-plane-approach-under-the-a1-pulley
#13
Mustafa T Yildizgören, Onur Velioglu, Hayal Guler
No abstract text is available yet for this article.
April 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/27047573/a-case-of-missed-ocular-torticollis
#14
Vahideh Toopchizadeh, Maryam Zolghadr, Reza Nabie
No abstract text is available yet for this article.
April 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/27047572/disease-modifying-antirheumatic-drugs-improve-cardiovascular-autonomic-neuropathy-in-psoriatic-arthritis
#15
Ashit Syngle, Inderjeet Verma, Pawan Krishan, Vijaita Syngle
BACKGROUND: Cardiovascular autonomic neuropathy (CAN) is a significant risk predictor for sudden cardiac death in autoimmune rheumatic diseases. As yet, there is no therapeutic treatment of CAN in psoriatic arthritis (PsA). Even now, the impact of the most commonly employed disease-modifying antirheumatic drug (DMARD) therapy on CAN in PsA is not known. Hence, we investigated the impact of DMARDs on CAN in PsA. METHODS: In this prospective, cross-sectional study, 20 patients of PsA and 20 age- and sex-matched healthy controls were recruited...
April 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/27047571/homologous-platelet-rich-plasma-for-the-treatment-of-knee-osteoarthritis-in-selected-elderly-patients-an-open-label-uncontrolled-pilot-study
#16
Carlo Bottegoni, Luca Dei Giudici, Sergio Salvemini, Enrico Chiurazzi, Rosella Bencivenga, Antonio Gigante
OBJECTIVE: The objective of this study was to evaluate the safety and the effect of platelet-rich plasma (PRP) intra-articular injections obtained from blood donors (homologous PRP) on elderly patients with early or moderate knee osteoarthritis (OA) who are not candidates for autologous PRP treatment. METHODS: A total of 60 symptomatic patients, aged 65-86 years, affected by hematologic disorders and early or moderate knee OA, were treated with 5 ml of homologous PRP intra-articular injections every 14 days for a total of three injections...
April 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/26834848/fibrin-glue-for-olecranon-bursitis-a-case-report
#17
David J Berkoff, Zachary W Sandbulte, Harry C Stafford, Joshua N Berkowitz
No abstract text is available yet for this article.
February 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/26834847/osteoporosis-in-men-findings-from-the-osteoporotic-fractures-in-men-study-mros
#18
REVIEW
Peggy M Cawthon, Mohammad Shahnazari, Eric S Orwoll, Nancy E Lane
The lifespan of men is increasing and this is associated with an increased prevalence of osteoporosis in men. Osteoporosis increases the risk of bone fracture. Fractures are associated with increased disability and mortality, and public health problems. We review here the study of osteoporosis in men as obtained from a longitudinal cohort of community-based older men, the Osteoporotic Fractures in Men Study (MrOS).
February 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/26834846/latest-therapeutic-advances-in-musculoskeletal-disease-from-the-acr-2015-annual-conference
#19
David M Reid, Gordon Mallarkey
No abstract text is available yet for this article.
February 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/26834845/osteoporosis-therapeutics-recent-developments-at-asbmr
#20
Gordon Mallarkey, David M Reid
No abstract text is available yet for this article.
February 2016: Therapeutic Advances in Musculoskeletal Disease
journal
journal
42615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"